ribosomal protein S29 pseudogene 2Genealiases: HsT23291 · RPS29_12_897
Q-omics provides the consensus-scored RPS29P2 profile across patient tissues and cancer cell-line models. RPS29P2 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, RPS29P2 is differentially expressed in 4, with the highest sampling consensus in BRCA. Additionally, RPS29P2 RNA expression shows 7,424 significant gene co-expression associations, with the highest sampling consensus in BRCA. Together, these results highlight LUSC, and BRCA as cancer lineages where RPS29P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS29P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS29P2 survival associations across molecular data types. RPS29P2 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS29P2 RNA expression–survival associations across cancer types. High RPS29P2 expression shows unfavorable associations in LUSC, ACC, BLCA, MESO and STAD, but favorable associations in ESCA. The LUSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify LUSC as the clearest survival context for RPS29P2 RNA expression.
This table summarizes RPS29P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for RPS29P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS29P2 shows lower tumor expression in BRCA, KIRC and KIRP and higher tumor expression in LUSC. The BRCA box plot shows higher RPS29P2 RNA expression in normal versus tumor tissue (log2 FC = −0.407, t-test p < 0.001).
This table shows molecular features associated with RPS29P2 in patient tissues and cancer cell lines. In patient samples, RPS29P2 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set.
